As a limitation of our study, demonstrating the efficacy of this treatment in one cell line does not fully demonstrate its efficacy in other ovarian cancer cell lines expressing RRM2. Although our previous studies have shown that RRM2 gene therapy may reduce the proliferation of SKOV3 cells in vivo and lead to an increase in apoptosis, the role of RRM2 gene therapy in different ovarian cancer types still requires further research. The gene discussed is RRM2; the disease is ovarian carcinoma.